Accel Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Accel Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$148K	Sell	35,935 -265	-0.7%	-$898	0.03%	302
2026 Q2	$133K	Sell	36,200 -3,000	-8%	-$10K	0.03%	300
2026 Q1	$120K	Sell	39,200 -1,000	-2%	-$3.86K	0.03%	284
2025 Q4	$164K	Sell	40,200 -4,000	-9%	-$19.8K	0.05%	271
2025 Q3	$216K	Hold	44,200	–	–	0.06%	253
2025 Q2	$224K	Buy	44,200 +150	+0.3%	+$737	0.07%	232
2025 Q1	$233K	Sell	44,050 -1,750	-4%	-$12.8K	0.08%	216
2024 Q4	$310K	Buy	+45,800	New	+$308K	0.12%	183
2023 Q3	–	Sell	-10,330	Closed	-$77.2K	–	179
2023 Q2	$77.2K	Buy	10,330 +4,230	+69%	+$29.6K	0.04%	167
2023 Q1	$40.7K	Buy	+6,100	New	+$48.4K	0.02%	522

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Accel Wealth Management's RXRX Position: Q3 2026 in Review

Accel Wealth Management reduced its Recursion Pharmaceuticals (RXRX) stake by 0.73% in Q3 2026, selling an estimated $898 and leaving 35,935 shares worth $148K. The position accounts for 0.03% of the portfolio, ranked #302.

Accel Wealth Management first reported a position in RXRX in Q1 2023 and has held it in 10 quarters since. The position peaked at $310K in Q4 2024. 144 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Accel Wealth Management held 35,935 shares of Recursion Pharmaceuticals worth $148K as of Q3 2026.
Accel Wealth Management sold 265 Recursion Pharmaceuticals shares in Q3 2026, an estimated $898.
Recursion Pharmaceuticals made up 0.03% of Accel Wealth Management's portfolio in Q3 2026, its #302 holding.
Accel Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
Accel Wealth Management's Recursion Pharmaceuticals position peaked at $310K in Q4 2024.
144 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Accel Wealth Management's 13F filing for Q3 2026, filed 13 Oct 2026.